Video

Red Flags And Dealbreakers in CDMO Selection

Source: Outsourced Pharma

In this segment of the Outsourced Pharma Live virtual event A New Age For Small Molecule Development, Bethany Dudek, Chief Technology Officer, Arcutis, and Sesha Neervannan, PhD, COO, Tarsus Pharmaceuticals discuss the importance of an established track record regarding quality and compliance. Neervannan also talks about other ways to evaluate a potential CDMO’s compatibility as a partner, such as response time to questions during the vetting phase prior to selection.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)